MYLAN PHARMS INC FDA Approval ANDA 208067

ANDA 208067

MYLAN PHARMS INC

FDA Drug Application

Application #208067

Documents

Letter2022-02-04

Application Sponsors

ANDA 208067MYLAN PHARMS INC

Marketing Status

None (Tentative Approval)001
None (Tentative Approval)002

Application Products

002CAPSULE;ORAL150MG0DABIGATRAN ETEXILATE MESYLATEDABIGATRAN ETEXILATE MESYLATE

FDA Submissions

UNKNOWN; ORIG1TA2022-01-21STANDARD

Submissions Property Types

ORIG1Null31

CDER Filings

MYLAN PHARMS INC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 208067
            [companyName] => MYLAN PHARMS INC
            [docInserts] => ["",""]
            [products] => [{"drugName":"DABIGATRAN ETEXILATE MESYLATE","activeIngredients":"DABIGATRAN ETEXILATE MESYLATE","strength":"75MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"},{"drugName":"DABIGATRAN ETEXILATE MESYLATE","activeIngredients":"DABIGATRAN ETEXILATE MESYLATE","strength":"150MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"01\/21\/2022","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/208067Orig1s000TA_ltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2022-01-21
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.